Safety study of a new drug for COVID-19
Part of Infections, Lungs & breathing clinical trials.
This early-phase trial tests a new drug (called B10-FC) to see if it's safe and how the body processes it. It is given once to healthy adults, and later to people with mild or moderate COVID-19 who are at higher risk of getting very sick.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old.
- You must be generally healthy, without major medical conditions.
- You must have a negative test for COVID-19 and no contact with COVID-19 patients in the past 14 days.
- You must not have taken steroids, monoclonal antibodies, or immunoglobulins recently.
- You must agree to use effective birth control for the entire trial.
- Your body mass index (BMI) must be between 18.5 and 30.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial tests an investigational drug called MDX2301 to see if it's safe in healthy adults and in adults who are at higher risk for severe COVID-19. Higher risk means you have conditions like asthma, diabetes, heart disease, or other listed health issues.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This is an early-stage safety study testing a new experimental drug called REGN22044 in people with no serious health conditions. Researchers want to understand how safe the drug is, how well people tolerate it, and how the body processes it.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.